These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 29730918

  • 1. [A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy].
    Zhang Y, Wang XQ, Liu H, Liu J, Hou W, Lin HS.
    Zhonghua Zhong Liu Za Zhi; 2018 Apr 23; 40(4):295-299. PubMed ID: 29730918
    [Abstract] [Full Text] [Related]

  • 2. [Clinical study on treatment of advanced non-small-cell lung cancer with Chinese herbal medicine in different stages combined with chemotherapy].
    Xu ZY, Jin CJ, Shen DY.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Oct 23; 27(10):874-8. PubMed ID: 17990450
    [Abstract] [Full Text] [Related]

  • 3. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, Chen JY, Niu XW, Su BR, Lu J, Wang ST.
    Ai Zheng; 2005 Oct 23; 24(10):1252-6. PubMed ID: 16219143
    [Abstract] [Full Text] [Related]

  • 4. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
    Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ.
    Complement Ther Med; 2016 Feb 23; 24():55-62. PubMed ID: 26860802
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial.
    Zhou ZY, Xu L, Li HG, Tian JH, Jiao LJ, You SF, Han ZF, Jiang Y, Guo HR, Liu H.
    J Integr Med; 2014 May 23; 12(3):175-81. PubMed ID: 24861837
    [Abstract] [Full Text] [Related]

  • 6. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 23; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer.
    Xue D, Han S, Jiang S, Sun H, Chen Y, Li Y, Wang W, Feng Y, Wang K, Li P.
    Med Oncol; 2015 Apr 23; 32(4):114. PubMed ID: 25772512
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of traditional Chinese Medicine combined with chemotherapy in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized clinical trials.
    Yang J, Zhu X, Yuan P, Liu J, Wang B, Wang G.
    Support Care Cancer; 2020 Aug 23; 28(8):3571-3579. PubMed ID: 32266566
    [Abstract] [Full Text] [Related]

  • 9. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.
    Li Y, Wang Y, Niu K, Chen X, Xia L, Lu D, Kong R, Chen Z, Duan Y, Sun J.
    Oncotarget; 2016 Oct 25; 7(43):70535-70545. PubMed ID: 27655708
    [Abstract] [Full Text] [Related]

  • 10. [Analysis of short-term therapeutic efficacy of integrated traditional and Western medicine in treating non-small cell lung cancer].
    Zhou DH, Lin LZ, Zhou YQ.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Dec 25; 25(12):1061-5. PubMed ID: 16398422
    [Abstract] [Full Text] [Related]

  • 11. [Safety and effectiveness of large dose compound Sophora flavescens Ait injection in the treatment of advanced malignant tumors].
    Li DR, Lin HS.
    Zhonghua Zhong Liu Za Zhi; 2011 Apr 25; 33(4):291-4. PubMed ID: 21575502
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N.
    Lancet Oncol; 2016 Jun 25; 17(6):822-835. PubMed ID: 27132212
    [Abstract] [Full Text] [Related]

  • 13. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
    Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J.
    BMC Complement Altern Med; 2012 Aug 01; 12():112. PubMed ID: 22853619
    [Abstract] [Full Text] [Related]

  • 14. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Jiang Y, Liu LS, Shen LP, Liu JX, Jiang GN, Gu AQ, Li HC, Li Q, Li HG, Huang PX.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e541-e547. PubMed ID: 31230892
    [Abstract] [Full Text] [Related]

  • 15. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ.
    Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045
    [Abstract] [Full Text] [Related]

  • 16. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.
    J Clin Oncol; 2017 Oct 20; 35(30):3449-3457. PubMed ID: 28854067
    [Abstract] [Full Text] [Related]

  • 17. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
    Lancet Oncol; 2015 Aug 20; 16(8):990-8. PubMed ID: 26159065
    [Abstract] [Full Text] [Related]

  • 18. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
    Yao J, Jiao L, Yao Y, Lu Y, Shi J, Li J, Chen P, Xu L, Gong Y.
    Trials; 2020 Apr 03; 21(1):309. PubMed ID: 32245480
    [Abstract] [Full Text] [Related]

  • 19. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer.
    Xue NZ, Fang RM, Lin LZ.
    Chin J Integr Med; 2014 Dec 03; 20(12):910-6. PubMed ID: 25428339
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP, EORTC Lung Cancer Group and the Italian Lung Cancer Project.
    Eur J Cancer; 2011 Oct 03; 47(15):2331-40. PubMed ID: 21802939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.